RxDoctor Payments Data

Sagar Damle, MD

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Atlanta, GANPI 1891832176

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,669 of the $13,154 with a category attached, or 65.9%. 39 manufacturers reported payments, led by Atricure, Inc. at 36.4% of the total. 2025 is the largest year on record at $3,237, more than ten times the $207 reported in 2019.

$13,154in general payments, 2019–2025

Across 232 payments — averaging $56.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$5K
  • JACE Medical LLC$2K
  • Abbott$2K
  • AstraZeneca$1K
  • Cvrx, Inc.$893
  • Abiomed$540
  • plus $3K from 33 others

What the payments were for

  • Consulting fees$1,57512%
  • Travel & lodging$2,86722%
  • Food & beverage$8,66966%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,154 in reported general payments places this provider in the 70th percentile of 144 thoracic surgery (cardiothoracic vascular surgery) providers in Georgia.

See all thoracic surgery (cardiothoracic vascular surgery) providers in Georgia

Medicare billing

Part B allowed, 2024
$166,689
Medicare patients
149
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$9,803
BrilintaTicagrelor16$6,961
Daptomycin12$5,424
Cefepime Hcl14$2,560
Sildenafil Citrate16$1,188
CeftriaxoneCeftriaxone Sodium18$684
Amiodarone Hcl17$444
ClopidogrelClopidogrel Bisulfate55$350
Hydralazine Hcl22$278
Gabapentin17$243
Atorvastatin Calcium35$218
Pantoprazole Sodium31$217
Digoxin14$208
Metoprolol Tartrate75$189
Torsemide13$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$1,171$6,96116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 144 thoracic surgery (cardiothoracic vascular surgery) providers in Georgia.

Other thoracic surgery (cardiothoracic vascular surgery) in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →